Immunovant Inc IMVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $32.67
- Day Range
- $30.78–32.88
- 52-Week Range
- $14.32–36.29
- Bid/Ask
- $30.00 / $30.89
- Shares Outstanding
- 205.31M
- Market Cap
- $6.39B
- Volume/Avg
- 872,075 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 315
- Website
- https://www.immunovant.com
Valuation
|
Metric
|
IMVT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.44 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMVT
|
|---|---|
Quick Ratio | 8.68 |
Current Ratio | 9.09 |
Interest Coverage | — |
Quick Ratio
IMVT
Profitability
|
Metric
|
IMVT
|
|---|---|
Return on Assets (Normalized) | −55.82% |
Return on Equity (Normalized) | −61.23% |
Return on Invested Capital (Normalized) | −63.95% |
Return on Assets
IMVT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Nfsbynrmj | Cqfzly | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Njcwhmvv | Zfxkt | $67B | |||
| argenx SE ADR
ARGX
| Nnmwmflq | Mkkn | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dtcwzwsdz | Qzqqqr | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Gshzltpr | Lcwbnqm | $25B | |||
| BioNTech SE ADR
BNTX
| Kmthqnzw | Qrcy | $22B | |||
| Incyte Corp
INCY
| Qrxxsblv | Wqn | $20B | |||
| Moderna Inc
MRNA
| Bygdhsggh | Mssl | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Fkvkvkczh | Wldv | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Dmmdbwyl | Vfyd | $13B |
United States